Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress
Provided By GlobeNewswire
Last update: Jun 11, 2025
– 7 of 8 myositis patients achieved clinically meaningful TIS responses after discontinuation of all immunomodulators, while off or actively tapering steroids; responses were sustained throughout the follow-up period in all responding patients –
Read more at globenewswire.com1.57
-0.13 (-7.65%)
Find more stocks in the Stock Screener
CABA Latest News and Analysis
17 days ago - ChartmillLet's have a look at the top gainers and losers one hour before the close of the markets of today's session.Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.
17 days ago - ChartmillTop movers analysis in the middle of the day on 2025-06-11: top gainers and losers in today's session.Curious about what's happening in today's session? Check out the latest stock movements and price changes.
17 days ago - ChartmillWhich stocks are gapping on Wednesday?Traders are paying attention to the gapping stocks in Wednesday's session. Let's dive into which stocks are experiencing notable gaps.
